Trial · NCT05332366

A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia

NCT05332366, Phase 2, Completed, LEO Pharma; results first posted 2025-02-07

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia. Trials, record NCT05332366. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05332366

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia
NCT number: NCT05332366
Status: Completed
Phases: Phase 2
Enrollment: 35 participants, actual
Lead sponsor: LEO Pharma
Conditions: Frontal Fibrosing Alopecia
Interventions: Delgocitinib cream, Delgocitinib cream vehicle
First posted: 2022-04-18
Last updated: 2025-03-06
Results first posted: 2025-02-07

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change in Expression of Chemokine (C-X-C Motif) Ligand 9 (CXCL9), Chemokine (C-X-C Motif) Ligand 10 (CXCL10), and Interferon (IFN)-γ From Baseline to Week 12.	Baseline and Week 12	CXCL9, CXCL10 and IFN-γ are small proteins that act as chemical messengers, especially in the immune system.
Secondary	Number of Treatment-emergent Adverse Events (TEAEs) From Baseline to Week 12.	Between baseline and Week 12	Treatment emergent adverse events (TEAEs) were defined as any AEs with onset date on or after the first study treatment dosing.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change in Expression of Chemokine (C-X-C Motif) Ligand 9 (CXCL9), Chemokine (C-X-C Motif) Ligand 10 (CXCL10), and Interferon (IFN)-γ From Baseline to Week 12.	Baseline and Week 12	No data was collected for No Treatment Arm/Groups.	Fold-changes	NUMBER
SECONDARY	Number of Treatment-emergent Adverse Events (TEAEs) From Baseline to Week 12.	Between baseline and Week 12	No investigational product was administered in Cohort 2 No Treatment Arm/Groups and thereby were no treatment-emergent AESIs reported in this trial for No Treatment Arm/Groups.	events	NUMBER

Source ClinicalTrials.gov

Results by group8

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
Change in Expression of Chemokine (C-X-C Motif) Ligand 9 (CXCL9), Chemokine (C-X-C Motif) Ligand 10 (CXCL10), and Interferon (IFN)-γ From Baseline to Week 12.	Delgocitinib - Delgocitinib	(C-X-C motif) ligand 9 (CXCL9)	-3.10	Fold-changes
Change in Expression of Chemokine (C-X-C Motif) Ligand 9 (CXCL9), Chemokine (C-X-C Motif) Ligand 10 (CXCL10), and Interferon (IFN)-γ From Baseline to Week 12.	Placebo - Delgocitinib	(C-X-C motif) ligand 9 (CXCL9)	-1.12	Fold-changes
Change in Expression of Chemokine (C-X-C Motif) Ligand 9 (CXCL9), Chemokine (C-X-C Motif) Ligand 10 (CXCL10), and Interferon (IFN)-γ From Baseline to Week 12.	Delgocitinib - Delgocitinib	Chemokine (C-X-C motif) ligand 10 (CXCL10)	-2.60	Fold-changes
Change in Expression of Chemokine (C-X-C Motif) Ligand 9 (CXCL9), Chemokine (C-X-C Motif) Ligand 10 (CXCL10), and Interferon (IFN)-γ From Baseline to Week 12.	Placebo - Delgocitinib	Chemokine (C-X-C motif) ligand 10 (CXCL10)	-1.10	Fold-changes
Change in Expression of Chemokine (C-X-C Motif) Ligand 9 (CXCL9), Chemokine (C-X-C Motif) Ligand 10 (CXCL10), and Interferon (IFN)-γ From Baseline to Week 12.	Delgocitinib - Delgocitinib	Interferon (IFN)-γ	-1.49	Fold-changes
Change in Expression of Chemokine (C-X-C Motif) Ligand 9 (CXCL9), Chemokine (C-X-C Motif) Ligand 10 (CXCL10), and Interferon (IFN)-γ From Baseline to Week 12.	Placebo - Delgocitinib	Interferon (IFN)-γ	-1.097	Fold-changes
Number of Treatment-emergent Adverse Events (TEAEs) From Baseline to Week 12.	Delgocitinib - Delgocitinib		4	events
Number of Treatment-emergent Adverse Events (TEAEs) From Baseline to Week 12.	Placebo - Delgocitinib		9	events

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Delgocitinib - Delgocitinib	15
Overall Study	STARTED	Placebo - Delgocitinib	15
Overall Study	STARTED	No Treatment	5
Overall Study	COMPLETED	Delgocitinib - Delgocitinib	15
Overall Study	COMPLETED	Placebo - Delgocitinib	15
Overall Study	COMPLETED	No Treatment	5
Overall Study	NOT COMPLETED	Delgocitinib - Delgocitinib	0
Overall Study	NOT COMPLETED	Placebo - Delgocitinib	0
Overall Study	NOT COMPLETED	No Treatment	0

Source ClinicalTrials.gov

Adverse events54

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Pain	General disorders	Delgocitinib - Delgocitinib	1	15	1
other	Pain	General disorders	Placebo - Delgocitinib	0	15	0
other	Pain	General disorders	No Treatment	0	0	0
other	COVID-19	Infections and infestations	Delgocitinib - Delgocitinib	1	15	1
other	COVID-19	Infections and infestations	Placebo - Delgocitinib	7	15	7
other	COVID-19	Infections and infestations	No Treatment	0	0	0
other	Pneumonia	Infections and infestations	Delgocitinib - Delgocitinib	0	15	0
other	Pneumonia	Infections and infestations	Placebo - Delgocitinib	1	15	1
other	Pneumonia	Infections and infestations	No Treatment	0	0	0
other	Upper respiratory tract infection	Infections and infestations	Delgocitinib - Delgocitinib	0	15	0

1 to 10 of 54Source ClinicalTrials.gov

See all 54 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Delgocitinib - Delgocitinib	0	15
Total, all-cause mortality	Placebo - Delgocitinib	0	15
Total, all-cause mortality	No Treatment	0	0
Total, other adverse events	Delgocitinib - Delgocitinib	6	15
Total, other adverse events	Placebo - Delgocitinib	10	15
Total, other adverse events	No Treatment	0	0
Total, serious adverse events	Delgocitinib - Delgocitinib	0	15
Total, serious adverse events	Placebo - Delgocitinib	0	15
Total, serious adverse events	No Treatment	0	0

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
41101628	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT05332366

GET https://conductscience.org/api/trials/v1/NCT05332366/events?page=2

API reference For AI assistants